Managed Access Program Cohort Treatment Plan CTMT212X2002I to Provide Access to Trametinib and Dabrafenib Combination Therapy for Patients With BRAF V600 Mutation-positive Advanced Non-Small Cell Lung Cancer

4. Is receiving care at a clinical site with a Treating Physician who has experience with administering investigational agents for the end-stage NSCLC population, or the patient is willing and/or able to travel to a site and receive treatment under the guidance of physician with this experience. NOTE: The latter option would require the patient being evaluated in advance by the Treating Physician at the experienced site and his/her agreement to assume responsibility for the care of the patient.

5. Is able to retain oral medication and swallow tablets/capsules (appropriate exceptions allowed for patients who are unable to swallow tablets/capsules - this is subject to availability of alternative (liquid) oral formulations).

6. Does not require treatment with any (other) anti-cancer medication (exceptions might be allowed and are subject to individual evaluation).

7. For patients with active brain metastases: the patient does not require or is ineligible for immediate local treatment.

9. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 3 (or equivalent) and is in stable clinical condition. NOTE: patient in rapidly deteriorating clinical condition prior to start of therapy should not be considered for this program.

10. Does not require treatment with prohibited concomitant medications.

Contraceptive Methods for Females of Childbearing Potential:

Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, must use highly effective methods of contraception during dosing and for 16 weeks after stopping treatment with trametinib (for trametinib monotherapy trials); 2 weeks after stopping treatment with dabrafenib (for dabrafenib monotherapy trials); 16 weeks after stopping treatment with trametinib or 2 weeks after stopping treatment with dabrafenib whichever is longer (for trials of dabrafenib in combination with trametinib).

Highly effective contraception methods include: (for dabrafenib monotherapy or combination therapy with trametinib)

* Total abstinence (when this is in line with the preferred and usual lifestyle of the subject). Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception.

* Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy), total hysterectomy, or tubal ligation at least six weeks before taking study treatment. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment.

* Sterilization (at least 6 months prior to screening) for male partners. The vasectomized male partner should be the sole partner for that subject.

* Placement of a hormonal or non-hormonal intrauterine device (IUD) or intrauterine system (IUS) with a documented failure rate of less than 1% per year.

Notes:

Double-barrier contraception: condom and occlusive cap (diaphragm or cervical/vault caps) with a vaginal spermicidal agent (foam/gel/cream/suppository) are not considered highly effective methods of contraception.

Hormonal-based methods (e.g. oral contraceptives) are not considered as highly effective methods of contraception due to potential drug-drug interactions with dabrafenib Women are considered post-menopausal and not of child bearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (i.e. age appropriate, history of vasomotor symptoms) or have had surgical bilateral oophorectomy (with or without hysterectomy), total hysterectomy, or tubal ligation at least six weeks ago. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment is she considered not of child bearing potential.

If a patient becomes pregnant during the treatment period of the program, the treatments should be stopped immediately.

12. Written patient informed consent must be obtained by the Treating Physician prior to start of treatment in accordance with the applicable local regulatory requirements.

Patients eligible for this Treatment Plan must not meet any of the following criteria:

1. Female who is pregnant or nursing (patient must discontinue nursing in order to enroll in the program).

NOTE: Safety and efficacy in pregnant or nursing women has not been investigated.

Inclusion of pregnant or nursing woman may be considered in individually upon review by the Novartis Country Pharma Organization Medical Advisor/Director.

2. Patients who have any lab abnormalities or AE/SAEs greater than Grade 3 (CTCAE v5.0).

3. Concurrent treatment with other systemic anti-cancer therapies is not allowed, with the exception of whole brain radiation and brain radiosurgery. Patients who are currently being treated with another systemic anti-cancer therapy (e.g., chemotherapy, immune, biologic, or targeted therapy) must discontinue use prior to initiation of treatment with trametinib and dabrafenib. NOTE: Radiation skin injury has been reported with concurrent use of dabrafenib and radiation. All AEs/SAEs related to WBRT (whole brain radiation) or brain radiosurgery are required to resolve to Grade 1 or less (CTCAE 5.0) prior to start of the program treatment.

4. Patients who have received prior therapy with a BRAF inhibitor other than dabrafenib.

NOTE: Consideration may be given to those patients who have either (1) received prior BRAF therapy and there is disease progression in the CNS only or (2) discontinued prior BRAF therapy due to an adverse event that is not likely to recur in response to treatment with Dabrafenib.

5. Presence of malignancy other than NSCLC within 1 year of enrolment into this program or any malignancy with confirmed activating RAS mutation. Patient with a history of completely resected non-melanoma skin cancer or successfully treated in situ carcinoma is eligible. NOTE: Prospective RAS testing is not required. However, if the results of previous RAS testing are known, they must be used in assessing eligibility.

6. Has a known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to trametinib or dabrafenib, or excipients or to dimethyl sulfoxide (DMSO).

7. Current evidence / risk of retinal vein occlusion (RVO) or central serous retinopathy.

8. Current evidence of cardiovascular risk including any of the following:

* LVEF\<LLN

* A QT interval corrected for heart rate using the Bazett's formula ≥ 480 msec;

* Clinically significant uncontrolled arrhythmias

* Acute coronary syndromes (including myocardial infarction and unstable angina).

* Congestive heart failure ≥ Class II as defined by New York Heart Association

9. Known history for testing positive for Human Immunodeficiency Virus (HIV).

10. Not able to understand and to comply with treatment instructions and requirements.

11. History of hypersensitivity to any drugs or metabolites of similar chemical classes as the product.

What this study is about